Press Releases

October 30, 2009

Bilcare announces its Q2 FY10 results

Click here to download PDF

Pune, October 30, 2009: The India Standalone Sales for the second quarter ended September 30, 2009 stood at Rs.135.32 crores as against Rs.118.61 crores in the same quarter of the previous year, showing a growth of 14%. This resulted in the EBITDA for India Standalone growing to Rs.39.07 crores from Rs.26.92 crores in the corresponding quarter of the previous year, showing a growth of 45%.

The Overseas business of the Company continued to show robust growth achieving Rs.127.96 crores in the second quarter of the current year from Rs.92.43 crores in corresponding quarter of the previous year, showing a growth of 38%. The EBITDA from Overseas business grew to Rs.23.33 crores from Rs.12.22 crores in the corresponding quarter of the previous year, resulting in a growth of 91%.

This resulted in Consolidated Sales for the quarter ended September 30, 2009 reaching Rs.263.28 crores, showing a growth of 25% over the corresponding quarter of the previous year; with the Consolidated EBITDA growing to Rs.62.39 crores from Rs.39.14 crores, a growth of 59%.

About Bilcare :

Headquartered in India, Bilcare is an integrated service provider to the global pharmaceutical sector across their value chain through its key business activities namely: Pharma Packaging Innovation, Global Clinical Services and Non-Clonable Technologies. These business activities encompass research, development, manufacturing and supply of products, processes, and services to the Pharma and Healthcare domain. Technologies business focuses on unique range of applications viz. security & product authentication, Track & Trace e-pedigree, medication compliance & Personalized Healthcare Management System. Bilcare operates state-of-the-art Manufacturing and Research facilities in India, Singapore, USA & UK and has regional offices in Brazil, Germany, China & Australia, while partnering with the global pharmaceutical sector by providing value solutions to address their key concerns i.e. counterfeit, compliance, cost communication and convenience.
(Visit us at www.bilcare.com)

Press Contact:

Bilcare Research
Tel: +91 20 30257700
Email: corpcomm@bilcare.com

Click here to view Financial Result